Breast cancer and depot-medroxyprogesterone acetate: A review
- 31 March 1994
- journal article
- review article
- Published by Elsevier in Contraception
- Vol. 49 (3) , 211-222
- https://doi.org/10.1016/0010-7824(94)90039-6
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Breast cancer and depot-medroxyprogesterone acetate: a multinational study: WHO COLLABORATIVE STUDY OF NEOPLASIA AND STEROID CONTRACEPTIVESThe Lancet, 1991
- Breast cancer and combined oral contraceptives: results from a multinational studyBritish Journal of Cancer, 1990
- Oral contraceptives and breast cancerBritish Journal of Cancer, 1990
- Oral contraceptive use influences resting breast proliferationHuman Pathology, 1989
- Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.BMJ, 1989
- POTENTIAL FOR BIAS IN CASE-CONTROL STUDIES OF ORAL CONTRACEPTIVES AND BREAST CANCERAmerican Journal of Epidemiology, 1988
- Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injectionsJAMA, 1983
- The Food and Drug Administration and medroxyprogesterone acetate. What are the issues?Published by American Medical Association (AMA) ,1983
- NONESTROGENIC DRUGS AND BREAST CANCERAmerican Journal of Epidemiology, 1982
- The association of depo-medroxyprogesterone acetate and breast cancerContraception, 1980